Navigation Links
Sequenom Announces Participation At Two Upcoming Investor Conferences
Date:9/12/2012

SAN DIEGO, Sept. 12, 2012 /PRNewswire/ --  Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Lazard Capital Markets Corporate Access Day in Boston, Mass., and the Credit Suisse 3rd Annual Small and Mid-Cap Conference, in New York.  

On Tuesday, September 18, Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will participate in the Lazard Capital Markets Corporate Access Day.  

Then, on Thursday, September 20, Dr. Lindsay will present at the Credit Suisse Small and Mid-Cap Conference, starting at 1:50 pm ET and will provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation webcast.  

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

(Logo:  http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
2. Sequenom Addresses Preliminary Injunction Decision, Reaffirms Defense of Patent
3. Sequenom Announces Appointment of Carolyn Beaver to Chief Accounting Officer
4. Sequenom Announces Participation at the Jefferies Global Healthcare Conference
5. Study In Prenatal Diagnosis Finds Sequenom CMMs MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets
6. Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
7. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
8. Sequenom Named to NASDAQ Global Select Market
9. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
10. Sequenom to Host Analyst Day on Monday, November 14, 2011
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... CAMBRIDGE, Mass. , Jan. 18, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal ... San Francisco . Napabucasin is ... pathways by targeting STAT3. i Cancer stem cells ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports ... A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long ... an anterior cervical discectomy and fusion on a 42 year old female who ...
(Date:1/18/2017)... ... ... from a new study are stating that if levels of the blood test called ... there is still remaining prostate cancer cells that are more likely to come back, spreading ... an indicator of whether a man’s prostate cancer is growing or not,” stated Dr. ...
(Date:1/18/2017)... , ... January 18, 2017 , ... Thirty-six startup companies ... credits by the Pennsylvania Department of Community and Economic Development in 2016 as part ... located in the University City Keystone Innovation Zone and represent the highest number of ...
Breaking Biology Technology:
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider ... introduction of Onitor Track, an innovative biometric data-driven program ... showcasing this month at the 2017 Consumer Electronics Show ... In the U.S., the World Health Organization ... than two-thirds of adults who are overweight or obese. ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):